# BSP-12-CADONILIMAB

## Executive Summary

| Property | Value |
|----------|-------|
| **Drug** | Cadonilimab |
| **Targets** | PD-1 Ã— CTLA-4 |
| **Indication** | Cervical/Gastric Cancer |
| **Innovation** | Optimized tetrameric variant with reduced immunogenicity |
| **Category** | Bispecific Antibody |

---

## V9 Scoring (Validated 2026-02-06)

| Metric | Score |
|--------|-------|
| **Patentability** | 6.75/10.0 |
| **In Silico Enablement** | 9.0/10.0 |
| **Commercial Value** | 7.5/10.0 |
| **Composite (P+S+C)** | 23.25/30.0 |
| **rNPV Estimate** | $95.0M |

---

## Sequence Validation

All antibody VH/VL sequences validated for correct framework features:
- Proper N-terminal framework residues (QVQL/EVQL for VH, DIVMTQ/DIQMTQ for VL)
- Conserved Cysteine residues for disulfide bonds
- JH/Jkappa joining regions present
- CDR3 sequences are specific (not generic)

**Status: VALIDATED** (2026-02-06)

---

## Computational Data

### Shared Data Repository

All computational data for this bispecific program lives in the shared data room:
**[Bispecific-BSP-02-ELRANATAMAB](https://github.com/nickharris808/Bispecific-BSP-02-ELRANATAMAB)**

| Directory | Files | Content |
|-----------|-------|---------|
| `01_reference_data/` | 117 | Boltz-2 (AlphaFold3) CIF structures, MSA files, confidence scores |
| `02_aggregation_analysis/` | 19 | Aggrescan3D APR mapping |
| `03_variant_designs/` | 45 | ProteinMPNN + RFdiffusion variant designs |
| `04_validation_results/` | 256 | EvoEF2 ddG, NetSolP solubility, ThermoMPNN, DeepImmuno |

### Validation Tools

Boltz-2 (AlphaFold3), DiffDock-L, ProteinMPNN, RFdiffusion, Aggrescan3D, NetSolP, ThermoMPNN, DeepImmuno

---

## Original Analysis

# BSP-12-CADONILIMAB

# BSP-12-CADONILIMAB

**Summary:** Optimized tetrameric PD-1 x CTLA-4 bispecific antibody variants with reduced immunogenicity and improved manufacturability for global market entry.

**Patentability Score:** 7.0/10
**In-Silico Score:** 9.0/10
**Gemini rNPV:** $250.0M

**Patentability Analysis:**
Cadonilimab (AK104) is prior art (approved 2022). Novelty relies on specific mutations reducing immunogenicity and aggregation. Patentability is strong as a selection invention if unexpected technical effects (e.g., reduced toxicity, better stability) are demonstrated against the parent molecule, addressing known limitations.

**In-Silico Analysis:**
Excellent computational validation using state-of-the-art tools including AlphaFold3 (Boltz-2) for structure, ProteinMPNN/RFdiffusion for variant design, and Aggrescan3D/DeepImmuno for developability. Comprehensive analysis of solubility, stability, and immunogenicity supports the claims.

